Hematology Today—June 2, 2026

LucidQuest

9 hours ago

This week’s Hematology update highlights ASCO 2026 readouts, regulatory milestones, and access updates across multiple myeloma, CLL, lymphoma, CMML, ITP, AML, and lower-risk MDS.

In Today’s Newsletter

Dive deeper

🧬 J&J TECVAYLI Phase 3 MajesTEC-9 data in multiple myeloma [1] [US / ASCO • 29 May 2026]

https://www.jnj.com/media-center/press-releases/new-tecvayli-data-demonstrates-superior-progression-free-and-overall-survival-as-early-as-first-relapse-in-multiple-myeloma
Context: In a population predominantly refractory to anti-CD38 therapy and lenalidomide, TECVAYLI reduced risk of disease progression or death by 71% and risk of death by 40%.
Key point: J&J reported that TECVAYLI showed clinically meaningful and statistically significant improvements in PFS and OS versus standard-of-care regimens in relapsed or refractory multiple myeloma treated as early as second line.
Implication: The data may support broader use of bispecifics earlier in the relapsed myeloma treatment sequence.

🩸 BeOne BRUKINSA 78-month CLL data at ASCO 2026 [2] [US / ASCO • 29 May 2026]

https://ir.beonemedicines.com/news/beone-medicines-establishes-standard-for-long-term-disease-control-in-cll-with-brukinsa-78-month-data-at/b4bd2456-0171-42db-b7ff-3dc5dea831a2
Context: The company also highlighted BRUKINSA plus sonrotoclax as a potential time-limited approach, with deep, durable, rapid uMRD responses.
Key point: BeOne presented 78-month BRUKINSA data in CLL, described as the longest reported follow-up for a next-generation BTK inhibitor in CLL.
Implication: The update reinforces long-term BTK inhibitor positioning in CLL and BeOne’s broader hematology franchise strategy.

💊 AbbVie VENCLYXTO EC expanded label in first-line CLL [3] [EU • 29 May 2026]

https://news.abbvie.com/2026-05-29-AbbVie-Announces-European-Commission-Authorization-of-Expanded-Label-for-VENCLYXTO-R-venetoclax-to-Include-Additional-Combinations-in-Previously-Untreated-Chronic-Lymphocytic-Leukemia
Context: The label expansion was supported by Phase 3 AMPLIFY, Phase 3 GLOW, and Phase 2 CAPTIVATE data.
Key point: The EC authorized an expanded VENCLYXTO label to include venetoclax plus acalabrutinib, with or without obinutuzumab, and venetoclax plus ibrutinib in previously untreated CLL.
Implication: Fixed-duration, chemotherapy-free oral combinations may give clinicians more flexibility in first-line CLL.

🧪 BMS mezigdomide Phase 3 SUCCESSOR-2 data in R/R multiple myeloma [4] [US / ASCO • 29 May 2026]

https://news.bms.com/news/corporate-financial/2026/Bristol-Myers-Squibb-Announces-CELMoD-Mezigdomide-Reduces-Risk-of-Disease-Progression-or-Death-by-More-than-50-vs–Standard-of-Care-in-Relapsed-or-Refractory-Multiple-Myeloma/default.aspx
Context: The regimen improved median PFS to 18 months versus 8.3 months for carfilzomib and dexamethasone alone, representing a 52% reduction in risk of progression or death.
Key point: BMS reported positive Phase 3 SUCCESSOR-2 results for mezigdomide plus carfilzomib and dexamethasone in R/R multiple myeloma.
Implication: First Phase 3 CELMoD data could strengthen the case for targeted protein degradation approaches in myeloma.

⚡ Solu STX-0712 FDA Fast Track designation in CMML [5] [US • 27 May 2026]

https://cdn.prod.website-files.com/669551ccc7908830b842dc2b/6a172dfa6204d20ba4f53b78_FDA%20Fast%20Track%20Designation%20for%20STX-0712.pdf
Context: STX-0712 is a CyTAC targeting CCR2-positive malignant monocytes and bone marrow blasts, with a Phase 1 study ongoing in R/R CMML and AML.
Key point: Solu Therapeutics received FDA Fast Track designation for STX-0712 in relapsed or refractory chronic myelomonocytic leukemia.
Implication: Fast Track status may increase FDA interaction frequency and support expedited development in a high-unmet-need blood cancer.

🛡️ Enterome EO2463 FDA Orphan Drug Designation in iNHL [6] [US / France • 28 May 2026]

https://www.enterome.com/news-events/enterome-receives-u-s-fda-orphan-drug-designation-for-eo2463-oncomimics-to-treat-watch-and-wait-indolent-non-hodgkin-lymphoma/
Context: EO2463 had previously received FDA Fast Track designation for follicular lymphoma in the watch-and-wait setting in October 2025.
Key point: Enterome received FDA Orphan Drug Designation for EO2463 in low-tumor-burden, “watch-and-wait” indolent non-Hodgkin lymphoma.
Implication: Orphan status adds regulatory and commercial advantages as Enterome seeks to advance EO2463 toward registrational development.

🧫 InnoCare orelabrutinib NDA acceptance in ITP in China [7] [China • 28 May 2026]

https://www.innocarepharma.com/en/news/activity/en020260528-NDA-Acceptance-for-Orelabrutinib-in-ITP-in-China
Context: InnoCare said this is the first NDA acceptance for orelabrutinib in autoimmune diseases, and no BTK inhibitors are currently approved in China for ITP.
Key point: China’s NMPA CDE accepted InnoCare’s NDA for orelabrutinib in primary immune thrombocytopenia.
Implication: Approval would expand orelabrutinib beyond hematologic malignancies into autoimmune disease.

🇨🇦 Daiichi Sankyo Vanflyta pCPA Letter of Intent in FLT3-ITD AML [8] [Canada • 28 May 2026]

https://www.newswire.ca/news-releases/daiichi-sankyo-concludes-pcpa-letter-of-intent-for-vanflyta-r-in-newly-diagnosed-flt3-itd-positive-aml-873945257.html
Context: Quebec began public reimbursement in May 2026, and the pCPA agreement enables reimbursement across induction, consolidation, and maintenance phases in Canada.
Key point: Daiichi Sankyo concluded a pCPA Letter of Intent for Vanflyta in newly diagnosed FLT3-ITD positive AML.
Implication: The agreement may broaden Canadian access to quizartinib across the full treatment course for eligible FLT3-ITD AML patients.

🧬 Agios tebapivat development update in lower-risk MDS [9] [US • 29 May 2026]

https://investor.agios.com/news-releases/news-release-details/agios-provides-update-phase-2b-trial-tebapivat-lower-risk
Context: The Phase 2b trial did not meet the company’s predefined threshold to support further development in LR-MDS, although tebapivat was well tolerated with no new safety signals.
Key point: Agios said it will not advance tebapivat in lower-risk myelodysplastic syndromes.
Implication: This narrows the near-term development path for tebapivat and shifts attention to Agios’ other rare-disease programs.

🧪 Incyte tafasitamab frontMIND Phase 3 data in high-risk DLBCL/HGBL [10] [US / ASCO • 30 May 2026]

https://investor.incyte.com/news-releases/news-release-details/incytes-pivotal-frontmind-trial-showed-tafasitamab
Context: The regimen reduced risk of disease progression or death by 25% versus R-CHOP alone, with data presented at ASCO 2026 and published in The Lancet.
Key point: Incyte reported Phase 3 frontMIND results for tafasitamab plus lenalidomide and R-CHOP in previously untreated high-risk DLBCL and HGBL.
Implication: The data support global regulatory submissions for tafasitamab and lenalidomide added to R-CHOP in first-line DLBCL.

Why it matters

ASCO 2026 delivered several hematology readouts that could reshape earlier-line use in multiple myeloma, CLL, and lymphoma.
Multiple myeloma remains especially active, with bispecific antibody and CELMoD data both pointing toward earlier relapse settings.
CLL treatment is continuing to move toward fixed-duration, oral, chemotherapy-free regimens.
Regulatory and access milestones remain important outside the US, including EU CLL label expansion, China NDA acceptance in ITP, and Canadian reimbursement progress in AML.
Several smaller biotechs advanced regulatory positioning in high-unmet-need hematologic diseases, including CMML and indolent NHL.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Hematology archive on our research hub page.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎯 Catch up on the Top Hematology news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What was the biggest multiple myeloma update this week?

J&J reported Phase 3 MajesTEC-9 data showing TECVAYLI improved PFS and OS versus standard-of-care regimens as early as second line, while BMS reported Phase 3 SUCCESSOR-2 data showing mezigdomide plus carfilzomib and dexamethasone reduced risk of progression or death by 52%. [1], [4]

What changed for VENCLYXTO in Europe?

The EC expanded VENCLYXTO’s label to include use with acalabrutinib, with or without obinutuzumab, and with ibrutinib for adults with previously untreated CLL. [3]

What did BeOne report for BRUKINSA?

BeOne presented 78-month CLL data at ASCO 2026, describing it as the longest reported follow-up for a next-generation BTK inhibitor in CLL. [2]

What is the significance of Solu’s FDA Fast Track designation?

Fast Track designation for STX-0712 may facilitate development and FDA review for relapsed or refractory CMML, a serious blood cancer with limited options. [5]

What happened with Agios’ tebapivat program in lower-risk MDS?

Agios will not advance tebapivat in LR-MDS after Phase 2b data did not meet the predefined threshold for further development in that indication. [9]

What is Incyte’s next step after frontMIND?

Incyte said the frontMIND data support global regulatory applications for tafasitamab and lenalidomide added to R-CHOP in previously untreated DLBCL. [10]

Entities / Keywords

Johnson & Johnson, TECVAYLI, teclistamab, MajesTEC-9, multiple myeloma, bispecific antibody, PFS, OS, ASCO 2026
BeOne Medicines, BRUKINSA, zanubrutinib, CLL, BTK inhibitor, sonrotoclax, BEQALZI, uMRD, SEQUOIA
AbbVie, VENCLYXTO, venetoclax, acalabrutinib, obinutuzumab, ibrutinib, CLL, European Commission, AMPLIFY, GLOW, CAPTIVATE
Bristol Myers Squibb, mezigdomide, CELMoD, SUCCESSOR-2, carfilzomib, dexamethasone, R/R multiple myeloma, targeted protein degradation
Solu Therapeutics, STX-0712, Fast Track, CMML, AML, CCR2, CyTAC
Enterome, EO2463, OncoMimics, Orphan Drug Designation, indolent non-Hodgkin lymphoma, follicular lymphoma
InnoCare, orelabrutinib, BTK inhibitor, ITP, NMPA, CDE, NDA, China
Daiichi Sankyo, Vanflyta, quizartinib, FLT3-ITD AML, pCPA, Canada, Quebec, QuANTUM-First
Agios, tebapivat, pyruvate kinase activator, lower-risk MDS, transfusion independence
Incyte, tafasitamab, Monjuvi, Minjuvi, lenalidomide, R-CHOP, frontMIND, DLBCL, HGBL